Patents by Inventor Ryo Dairiki

Ryo Dairiki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TAU-TARGETING OLIGONUCLEOTIDE GAPMERS
    Publication number: 20220195437
    Abstract: Antisense oligonucleotides are provided. These antisense oligonucleotides are useful in the preparation of gapmers for inhibition of Tau mRNA transcription. Inhibition of Tau mRNA transcription may result in decrease of amounts of Tau protein in a subject, allowing treatment of diseases and disorders related to expression of Tau, including Alzheimer's disease and primary tauopathies.
    Type: Application
    Filed: December 10, 2021
    Publication date: June 23, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Hyeong-Wook CHOI, Francis G. FANG, Yoshinori TAKAHASHI, Kenji KIKUTA, Hikaru YOSHIMURA, Wataru ITANO, Toshiki KUROKAWA, Ryo DAIRIKI, Zhi ZHOU, Mingde SHAN
  • Method of predicting effects of CDC7 inhibitor
    Patent number: 11155879
    Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: October 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akihiro Ohashi, Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki, Yuko Ishii
  • BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST
    Publication number: 20210123919
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 29, 2021
    Applicants: Merck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro FUNAHASHI, Kotaro KODAMA, Ryo DAIRIKI, Yukinori MINOSHIMA
  • METHOD OF PREDICTING EFFECTS OF CDC7 INHIBITOR
    Publication number: 20200010904
    Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.
    Type: Application
    Filed: March 1, 2017
    Publication date: January 9, 2020
    Inventors: Akihiro Ohashi, Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki, Yuko Ishil